Marije M. Löwik

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients

Clemens von Birgelen, Mounir W.Z. Basalus, Kenneth Tandjung et al. · Journal of the American College of Cardiology · 2012 · 247 citations · Full text

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

Clemens von Birgelen, Marlies M. Kok, Liefke C. van der Heijden et al. · The Lancet · 2016 · 246 citations · Full text

Percutaneous Coronary Intervention, Cardiovascular Disease, Atherosclerosis +8

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

Clemens von Birgelen, Hanim Sen, Ming Kai Lam et al. · The Lancet · 2013 · 198 citations

Dutch Peers, Percutaneous Coronary Intervention, Thrombosis +13

Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in Children

Henriette A.C. Kyrieleis, Marije M. Löwik, Ilse Pronk et al. · Clinical Journal of the American Society of Nephrology · 2009 · 143 citations · Full text

Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation

Marije M. Löwik, Patricia J.T.A. Groenen, Ilse Pronk et al. · Kidney International · 2007 · 137 citations

Glomerular Disease, Glomerulonephritis, Focal Segmental Glomerulosclerosis +7